ALNOV:EPA
Novacyt SA
0,46 €
arrow_downward
-0,32%(-0,0015) 1 d.
20. okt., 17:35:20 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,47 €
Augsta
0,47 €
Zema
0,46 €
Tirgus kapitalizācija
35,39 milj.
Vid. apjoms
235,63 tūkst.
Apjoms
100,54 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,37 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,47 €
Augsta
0,47 €
Zema
0,46 €
Tirgus kapitalizācija
35,39 milj.
Vid. apjoms
235,63 tūkst.
Apjoms
100,54 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,37 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Business Journals
·
pirms 19 minūtēm
Tualatin startup says Nasdaq listing on course despite SPAC issue
Quiver Quantitative
·
pirms 28 minūtēm
SEGG Media Receives Nasdaq Staff Determination Letter Over Late Quarterly Filing, Requests Hearing and Extended Stay
PR Newswire
·
pirms 35 minūtēm
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
·
pirms 1 stundas
QCR Holdings (NASDAQ:QCRH) Reports Sales Below Analyst Estimates In Q3 2026 Earnings
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
Sektors-
Tīmekļa vietnenovacyt.com